Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy
Acta Pharmaceutica Sinica B · 2023-02 · 13 (2) · 787-803
DOI: 10.1016/j.apsb.2022.08.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-02. Verfasst von Yijun Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Bi…. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education of the People's Republic of China, State Administration of Foreign Experts Affairs, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is an autoimmune disease characterized by severe synovial inflammation and cartilage damage. Despite great progress in RA therapy, there still lacks the drugs to completely cure RA patients. Herein, we propose a reprogrammed neutrophil cytopharmaceuticals loading with TNFα-targeting-siRNA (siTNFα) as an alternative anti-inflammatory approach for RA treatment. The loaded siTNFα act as not only the gene therapeutics to inhibit TNFα production by macrophages in inflamed synovium, but also the editors to reprogram neutrophils to anti-inflammatory phenotypes. Leveraging the active tendency of neutrophils to inflammation, the reprogrammed siTNFα/neutrophil cytopharmaceuticals (siTNFα/TP/NEs) can rapidly migrate to the inflamed synovium, transfer the loaded siTNFα to macrophages followed by the significant reduction of TNFα expression, and circumvent the pro-inflammatory activity of neutrophils, thus leading to the alleviated synovial inflammation and improved cartilage protection. Our work provides a promising cytopharmaceutical for RA treatment, and puts forward a living neutrophil-based gene delivery platform.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, China.
Förderung
- Ministry of Education of the People's Republic of China
- State Administration of Foreign Experts Affairs
- Natural Science Foundation of Jiangsu Province
- State Key Laboratory of Natural Medicines
- Double First Class University Plan
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Li, K., Jiao, M., Huang, Y., Zhang, Z., Xue, L., Ju, C., & Zhang, C. (2023). Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy. Acta Pharmaceutica Sinica B, 13(2), 787-803. https://doi.org/10.1016/j.apsb.2022.08.012
Vancouver
Chen Y, Li K, Jiao M, Huang Y, Zhang Z, Xue L, et al. Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy. Acta Pharmaceutica Sinica B. 2023;13(2):787-803. doi:10.1016/j.apsb.2022.08.012
BibTeX
@article{Chen2023,
author = {Chen, Yijun and Li, Kaiming and Jiao, Mengying and Huang, Yingshuang and Zhang, Zihao and Xue, Lingjing and Ju, Caoyun and Zhang, Can},
title = {Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {2},
pages = {787--803},
doi = {10.1016/j.apsb.2022.08.012}
}
EUVIMED